Bezafibrate SR Tablets 200mg (Bezafibrate SR Tablets Sawai® / ベザフィブラートSR錠200mg「サワイ」)

JPY ¥2,000

Japanese Antihyperlipidemic Agent (Bezafibrate 200mg). Oral sustained-release tablet for treatment of hyperlipidemia including familial hyperlipidemia. 100 tablets (10 tablets x 10). Mfd. by Sawai Pharmaceutical Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥1,840
10 - 19 12% JPY ¥1,760
20 + 18% JPY ¥1,640
SKU: BEZ-200-TAB Category:

Description

Product Overview / 商品概要

Bezafibrate SR Tablets 200mg “Sawai” (ベザフィブラートSR錠200mg「サワイ」)
Generic: Bezafibrate / ベザフィブラート
Therapeutic Category: Antihyperlipidemic Agent / 高脂血症治療剤
Manufactured by: Sawai Pharmaceutical Co., Ltd. / 沢井製薬株式会社

Composition & Specification / 組成・規格

Active Ingredient: Bezafibrate (JP) 200mg per tablet / 1錠中 日局ベザフィブラート 200mg
Additives: Carnauba wax, Light anhydrous silicic acid, Microcrystalline cellulose, Titanium oxide, Magnesium stearate, Talc, Hydroxypropylcellulose, Hypromellose, Macrogol 6000 / カルナウバロウ、軽質無水ケイ酸、結晶セルロース、酸化チタン、ステアリン酸Mg、タルク、ヒドロキシプロピルセルロース、ヒプロメロース、マクロゴール6000
Appearance: White to yellowish-white, sustained-release film-coated tablet; diameter 9.1mm, thickness 4.8mm, weight approx. 258mg, identification code: SW 422
外観: 白色~帯黄白色、徐放性フィルムコーティング錠、直径9.1mm、厚さ4.8mm、重量約258mg、識別コード SW 422

Indications / 効能効果

EN: Hyperlipidemia (including familial hyperlipidemia)
JA: 高脂血症(家族性を含む)

Dosage and Administration / 用法用量

EN: Usually, adults are administered 400mg of bezafibrate per day orally in two divided doses after morning and evening meals. Dose reduction should be considered as appropriate for patients with renal impairment and elderly patients.
JA: 通常、成人にはベザフィブラートとして1日400mgを2回に分けて朝夕食後に経口投与する。なお、腎機能障害を有する患者及び高齢者に対しては適宜減量すること。

Contraindications / 禁忌

EN: Patients on artificial dialysis (including peritoneal dialysis); patients with severe renal disease such as renal failure; patients with serum creatinine ≥2.0mg/dL; patients with a history of hypersensitivity to any component of this product; pregnant women or women who may be pregnant
JA: 人工透析患者(腹膜透析を含む)、腎不全などの重篤な腎疾患のある患者、血清クレアチニン値が2.0mg/dL以上の患者、本剤の成分に対し過敏症の既往歴のある患者、妊婦又は妊娠している可能性のある女性

Regulatory Information / 規制情報

Approval No.: 22400AMX00126000
Sales Started: July 1998 / 1998年7月
Classification Code: 872183
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 100 tablets (10 tablets x 10) / 100錠(10錠×10)
Other Available Packages (by special order): PTP: 100 tablets (10 tablets x 10), 500 tablets (10 tablets x 50)

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Bezafibrate SR Tablets 200mg (Bezafibrate SR Tablets Sawai® / ベザフィブラートSR錠200mg「サワイ」)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Bezafibrate SR Tablets 200mg (Bezafibrate SR Tablets Sawai®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.